Abstract
Neuroendocrine carcinoma (NEC) of the large intestine is a rare and highly aggressive malignancy with an extremely poor prognosis. We report the case of a 70-year-old male who presented with constipation and abdominal bloating. Diagnostic imaging revealed a sigmoid colon tumor and multiple liver metastases. Following a palliative transverse colostomy, an intraoperative biopsy confirmed the diagnosis of high-grade NEC. Despite the administration of five cycles of cisplatin and irinotecan (IP) therapy, the disease progressed rapidly, leading to the patient's death seven months after initial presentation. This case highlights the clinical challenges of managing metastatic NEC and the urgent need for standardized second-line treatment protocols.
Introduction
Neuroendocrine carcinomas (NEC) of the colon and rectum are rare, accounting for less than 1% of all colorectal cancers. Unlike well-differentiated neuroendocrine tumors (NET), NECs are characterized by high-grade cytological features, rapid proliferation, and early systemic metastasis. Due to their rarity, dedicated clinical trials are scarce, and treatment strategies are often adapted from small cell lung cancer (SCLC) protocols, typically involving platinum-based chemotherapy.
Case Presentation
A 70-year-old male presented with symptoms of sub-total bowel obstruction. Enhanced CT imaging identified a 70×50 mm primary tumor in the sigmoid colon and extensive bilobar liver metastases. To alleviate the obstruction and prepare for systemic therapy, a transverse colostomy was performed.
Diagnosis and Pathology
Intraoperative endoscopic biopsy was performed for definitive diagnosis. Histopathological examination using Hematoxylin and Eosin (HE) staining revealed atypical cells arranged in solid nests. Immunohistochemical (IHC) analysis was critical in confirming the neuroendocrine origin and high-grade nature of the tumor:
- Ki-67 Index: >80%, indicating an extremely high rate of cell proliferation.
- Synaptophysin: Positive staining confirmed neuroendocrine differentiation.
- CK8/18: Positive staining was observed.
Based on these findings and the 2019 WHO classification, the tumor was diagnosed as a high-grade neuroendocrine carcinoma.
Clinical Course and Treatment
Following the "Pancreatico-Gastrointestinal Neuroendocrine Neoplasm Clinical Practice Guidelines," the patient was initiated on IP therapy (Irinotecan + Cisplatin). The regimen was administered in 4-week cycles to balance therapeutic efficacy with the patient's performance status and quality of life (QoL).
The patient completed five courses of IP therapy. While the disease was initially classified as stable (SD), tumor markers (CEA and CA19-9) began to rise sharply after 180 days. Subsequent imaging confirmed disease progression. Due to declining renal function (creatinine clearance <40 ml/min), chemotherapy was discontinued. The patient transitioned to palliative care and passed away 221 days after his first visit.
Discussion
This case underscores the aggressive nature of colorectal NEC. Despite an initial period of stabilization, the tumor eventually bypassed the platinum-based regimen. A significant clinical hurdle identified in this case is the lack of established second-line therapies once first-line platinum agents fail or become contraindicated due to toxicity (such as renal impairment).
The decision to prioritize QoL by adjusting the chemotherapy schedule allowed the patient to remain at home for the majority of his remaining months. However, the overall survival of approximately seven months aligns with the poor outcomes reported in existing literature for metastatic NEC, where survival rarely exceeds one year.
Conclusion
Metastatic neuroendocrine carcinoma of the sigmoid colon remains a therapeutic challenge with a dire prognosis. While platinum-based combinations like Irinotecan and Cisplatin are the current standard, they often provide only transient benefits. Further accumulation of clinical cases and the development of standardized second-line treatments are essential to improve outcomes for patients with this aggressive malignancy.
Summary updated